Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains

Current Drug Discovery Technologies

Volumn 11, Issue 1, 2014, Pages 28-40

  Chen, Weizao ^a   Gong, Rui ^a   Ying, Tianlei ^a   Prabakaran, Ponraj ^a,b   Zhu, Zhongyu ^a   Feng, Yang ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Antibody domains; Human; Library; Phage display; Scaffold; Stability; Therapeutics; Yeast display

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY;

ANTIBODY LIBRARY; ARTICLE; DISULFIDE BOND; HUMAN IMMUNODEFICIENCY VIRUS 1; INDEL MUTATION; NONHUMAN; PHAGE DISPLAY; POINT MUTATION; PRIORITY JOURNAL; SOMATIC HYPERMUTATION;

ANIMALS; ANTIBODIES; DRUG DISCOVERY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY;

EID: 84900869871     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/15701638113109990032     Document Type: Article

References (62)

1. Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 2004; 279: 1256-61.
2. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-36.
3. de Marco A. Biotechnological applications of recombinant singledomain antibody fragments. Microb Cell Fact 2011; 10: 44.
4. Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009; 198: 157-74.
5. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: Proteins for therapy. Trends Biotechnol 2003; 21: 484-90.
6. Stanfield RL, Dooley H, Flajnik MF, Wilson IA. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 2004; 305: 1770-3.
7. Bloom L, Calabro V. FN3: A new protein scaffold reaches the clinic. Drug Discov Today 2009; 14: 949-55.
8. Owens RM, Gu X, Shin M, Springer TA, Jin MM. Engineering of single Ig superfamily domain of intercellular adhesion molecule 1 (ICAM-1) for native fold and function. J Biol Chem 2010; 285: 15906-15.
9. Bruning M, Barsukov I, Franke B, et al. The intracellular Ig fold: A robust protein scaffold for the engineering of molecular recognition. Protein Eng Des Sel 2012; 25: 205-12.
10. Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325: 531-53.
11. Ewert S, Cambillau C, Conrath K, Pluckthun A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 2002; 41: 3628-36.
12. Dimitrov DS. Engineered CH2 domains (nanoantibodies). MAbs 2009; 1: 26-8.
13. Gong R, Wang Y, Ying T, Dimitrov DS. Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn. PLoS ONE 2012; 7: E42288.
14. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008; 105: 17121-6.
15. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008; 382: 779-89.
16. Chen W, Feng Y, Zhao Q, Zhu Z, Dimitrov DS. Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics. Mol Cancer Ther 2012; 11: 1400-10.
17. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-8.
18. Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995; 374: 168-73.
19. Berman H, Henrick K, Nakamura H, Markley JL. The worldwide Protein Data Bank (wwPDB): Ensuring a single, uniform archive of PDB data. Nucleic Acids Res 2007; 35: D301-3.
20. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Engineering 1994; 7: 1129-35.
21. Flajnik MF, Deschacht N, Muyldermans S. A case of convergence: Why did a simple alternative to canonical antibodies arise in sharks and camels PLoS Biol 2011; 9: E1001120.
22. Dottorini T, Vaughan CK, Walsh MA, LoSurdo P, Sollazzo M. Crystal structure of a human VH: Requirements for maintaining a monomeric fragment. Biochemistry 2004; 43: 622-8.
23. Conrath K, Vincke C, Stijlemans B, et al. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol 2005; 350: 112-25.
24. Jespers L, Schon O, James LC, Veprintsev D, Winter G. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J Mol Biol 2004; 337: 893-903.
25. Schiefner A, Chatwell L, Korner J, et al. A disulfide-free singledomain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J Mol Biol 2011; 414: 337-55.
26. Prabakaran P, Vu BK, Gan J, Feng Y, Dimitrov DS, Ji X. Structure of an isolated unglycosylated antibody C(H)2 domain. Acta Crystallogr D Biol Crystallogr 2008; 64: 1062-7.
27. Gong R, Vu BK, Feng Y, et al. Engineered human antibody constant domains with increased stability. J Biol Chem 2009; 284: 14203-10.
28. Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS. Shortened engineered human antibody CH2 domains: Increased stability and binding to the human neonatal Fc receptor. J Biol Chem 2011; 286: 27288-93.
29. Gehlsen K, Gong R, Bramhill D, et al. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs 2012; 4: 466-74.
30. Smith GP. Filamentous Fusion Phage-Novel Expression Vectors That Display Cloned Antigens on the Virion Surface. Science 1985; 228: 1315-7.
31. Beerli RR, Bauer M, Buser RB, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci USA 2008; 105: 14336-41.
32. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997; 15: 553-7.
33. Francisco JA, Earhart CF, Georgiou G. Transport and anchoring of beta-lactamase to the external surface of Escherichia coli. Proc Natl Acad Sci USA 1992; 89: 2713-7.
34. Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997; 94: 4937-42.
35. Dooley H, Flajnik MF, Porter AJ. Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol 2003; 40: 25-33.
36. Suzuki T, Shin T, Fujiyama A, Kohara Y, Kasahara M. Hagfish leukocytes express a paired receptor family with a variable domain resembling those of antigen receptors. J Immunol 2005; 174: 2885-91.
37. Xu G, Tasumi S, Pancer Z. Yeast surface display of lamprey variable lymphocyte receptors. Methods Mol Biol 2011; 748: 21-33.
38. Davies J, Riechmann L. Antibody Vh Domains as Small Recognition Units. Bio-Technology 1995; 13: 475-9.
39. Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Engineering Design & Selection 2010; 23: 155-9.
40. Tasumi S, Velikovsky CA, Xu G, et al. High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci USA 2009; 106: 12891-6.
41. Zhao Q, Zhu Z, Dimitrov DS. Yeast display of engineered antibody domains. Methods Mol Biol 2012; 899: 73-84.
42. Beerli RR, Rader C. Mining human antibody repertoires. MAbs 2010; 2.
43. Jirholt P, Ohlin M, Borrebaeck CA, Soderlind E. Exploiting sequence space: Shuffling in vivo formed complementarity determining regions into a master framework. Gene 1998; 215: 471-6.
44. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics 2006; 22: 195-201.
45. Chen W, Zhu Z, Feng Y, Dimitrov DS. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol Immunol 2010; 47: 912-21.
46. Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS. A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitors. Biochem Biophys Res Commun 2009; 387: 387-92.
47. Ying T, Chen W, Gong R, Feng Y, Dimitrov DS. Soluble monomeric IgG1 Fc. J Biol Chem 2012; 287: 19399-408.
48. Wozniak-Knopp G, Bartl S, Bauer A, et al. Introducing antigenbinding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23: 289-97.
49. Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010; 2: 347-56.
50. Persson MA. Twenty years of combinatorial antibody libraries, but how well do they mimic the immunoglobulin repertoire Proc Natl Acad Sci USA 2009; 106: 20137-8.
51. Prabakaran P, Chen W, Singarayan MG, et al. Expressed antibody repertoires in human cord blood cells: 454 sequencing and IMGT/HighV-QUEST analysis of germline gene usage, junctional diversity, and somatic mutations. Immunogenetics 2012; 64: 337-50.
52. Prabakaran P, Zhu Z, Chen W, et al. Origin, diversity, and maturation of human antiviral antibodies analyzed by highthroughput sequencing. Front Microbiol 2012; 3: 277.
53. Prabakaran P, Streaker E, Chen W, Dimitrov DS. 454 antibody sequencing-error characterization and correction. BMC Res Notes 2011; 4: 404.
54. Alamyar E, Giudicelli V, Duroux P, Lefranc MP. IMGT/HighVQUEST: A High-Throughput System and Web Portal for the Analysis of Rearranged Nucleotide Sequences of Antigen Receptors. In: Journées Ouvertes en Biologie, Informatique et Mathématiques. Montpellier, France; 2010. pp. P63.
55. Dudgeon K, Famm K, Christ D. Sequence determinants of protein aggregation in human VH domains. Protein Eng Des Sel 2009; 22: 217-20.
56. Reddy ST, Ge X, Miklos AE, et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol 2010; 28: 965-9.
57. Xiao X, Chen W, Feng Y, Dimitrov DS. Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Viruses 2009; 1: 802-17.
58. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
59. Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77: 10557-65.
60. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 2010; 88: 107-15.
61. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006; 5: 114-20.
62. Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010; 16: 121-9.